Membranous glomerulonephritis

Membranous glomerulonephritis is a reported renal manifestation of hepatitis C virus infection and one of the less common glomerular lesions linked to the virus. It can occur in native kidneys and may also develop de novo after kidney transplantation, where its clinical importance lies less in its frequency than in its association with nephrotic syndrome and the broader threat of hepatitis C–related injury to the renal allograft.

Definition and Clinical Setting

Membranous glomerulonephritis belongs to the range of glomerular diseases reported in patients with hepatitis C virus infection. The predominant hepatitis C–associated renal lesion is cryoglobulinemic membranoproliferative glomerulonephritis, generally associated with type II mixed cryoglobulinemia; membranous glomerulonephritis is less common and therefore occupies a secondary position in the disease spectrum. Other reported lesions include membranoproliferative glomerulonephritis without cryoglobulinemia, focal segmental glomerular sclerosis, proliferative glomerulonephritis, and fibrillary or immunotactoid glomerulopathies.

The broader clinical context is systemic rather than confined to the liver. Hepatitis C virus infection may produce autoimmune, dermatological, and renal disease, and its renal manifestations can appear alongside extrahepatic syndromes such as mixed cryoglobulinemia. In patients with active chronic infection, assessment therefore requires both confirmation of viremia and evaluation of hepatic and extrahepatic injury. Active infection is defined by the combination of anti-HCV positivity and detectable HCV RNA, while liver damage may be assessed by biopsy or noninvasive fibrosis measures such as FibroScan.

Occurrence in Renal Allografts

After kidney transplantation, hepatitis C virus infection can produce de novo glomerulopathies and thereby impair allograft function. Membranous glomerulonephritis has been specifically described as an HCV-associated lesion in renal allografts, and it is also the most frequent type of de novo glomerulonephritis reported in HCV-negative renal allografts. This overlap makes the transplant setting diagnostically complex: the lesion is recognizable, but its association with hepatitis C cannot be assumed from morphology alone.

The clinical presentation in an HCV-infected allograft is usually nephrotic syndrome. Unlike HCV-related membranoproliferative glomerulonephritis, however, membranous glomerulonephritis generally lacks a clear pathogenic bridge to the virus. Cryoglobulins, circulating immune complexes, and complement activation are usually absent, leaving the causal relationship between hepatitis C and membranous glomerulonephritis unresolved. The contrast is important because HCV-related membranoproliferative disease is supported by evidence of type II mixed cryoglobulinemia and by high concentrations of HCV RNA in the cryocrit, whereas the same explanatory pattern is not ordinarily found in membranous disease.

Diagnosis and Pathological Overlap

Diagnosis in renal transplant recipients may be difficult because glomerular lesions can coexist with, or be obscured by, immunological injury to the graft. The prevalence of glomerular lesions in HCV-positive renal allografts varies according to whether protocol biopsies or biopsies performed for clinical indications are analyzed; estimates range from 5% to 15%. Mild abnormalities and overlapping forms of immunological damage can further complicate pathological classification.

Membranous glomerulonephritis must be distinguished from other causes of post-transplant proteinuria and from lesions such as transplant glomerulopathy. In HCV-associated membranoproliferative glomerulonephritis, electron microscopy shows subendothelial electron-dense deposits, whereas transplant glomerulopathy is characterized by radiolucent areas in the glomerular basement membrane. Although these findings concern different lesions, they illustrate the diagnostic problem surrounding an HCV-infected allograft: immune-complex disease, autoimmunity, and transplant-specific injury may overlap, and in some cases membranoproliferative glomerulonephritis and transplant glomerulopathy coexist.

Consequences for the Graft

The diagnosis of de novo glomerulonephritis in an HCV-infected renal allograft is clinically consequential because such disease is associated with accelerated graft loss. Hepatitis C virus infection itself is a major independent risk factor for renal allograft loss, although part of its apparent effect may reflect the high immunological risk of the infected transplant population. Many HCV-infected recipients have undergone retransplantation, lived with renal disease for longer periods, or developed heightened cellular and humoral immune responses, all of which can complicate interpretation of graft injury.

Membranous glomerulonephritis therefore sits within a larger pattern of vulnerability. HCV-infected allograft recipients are prone to immune complex-mediated glomerulonephritis, as are nontransplanted patients, and post-transplant proteinuria may be an early clinical signal of this process. A prior graft lost to de novo HCV-related glomerulonephritis may be followed by an earlier and more aggressive recurrence in a subsequent transplant, emphasizing the long-term consequences of glomerular disease even when the specific mechanism of membranous glomerulonephritis remains uncertain.

Relation to Antiviral Management

Because hepatitis C can injure both the liver and the transplanted kidney, treatment strategy is directed in part toward preventing HCV-related allograft disease. Antiviral eradication is considered preferable before transplantation, while the patient remains on dialysis, in order to reduce the risk of recurrent or de novo HCV-associated renal disease after transplantation. In the period after transplantation, interferon-based treatment with or without ribavirin has been described mainly for exceptional situations, including rapidly progressive cirrhosis, fibrosing cholestatic hepatitis, or de novo cryoglobulinemic glomerulonephritis within the allograft.

That therapeutic pattern also clarifies the position of membranous glomerulonephritis. Although it is a recognized HCV-associated lesion, the absence of a consistent cryoglobulin, immune-complex, or complement-mediated mechanism means that the evidence does not establish it as a direct viral complication in the same way as cryoglobulinemic membranoproliferative glomerulonephritis. Its significance lies in the diagnostic and prognostic landscape of HCV-positive transplantation: nephrotic syndrome, proteinuria, pathological overlap, and possible graft loss require attention even when the precise link between viral infection and membranous injury cannot be demonstrated.